A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: JNJ-64232025 SC; Drug: JNJ-64232025 IV; Drug: Placebo

• Registration Number: NCT03550950
• Lead Sponsor: Janssen Research & Development, LLC

Brief Summary

The purpose of this study is to assess the safety and tolerability of JNJ-64232025 following single ascending intravenous (IV) study intervention administrations and a single subcutaneous (SC) intervention administration in healthy participants.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-05-29
• Study First Submitted QC: 2018-05-29
• Study Start: 2018-06-01
• Study First Posted: 2018-06-11
• Status Verified: 2019-02
• Primary Completion: 2019-02-05
• Study Completion: 2019-02-05
• Last Update Submitted: 2019-02-26
• Last Update Posted: 2019-02-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Male or female of non-childbearing potential (postmenopausal or permanently sterile)
• Have a body mass index (BMI) between 19 and 30 kilogram per meter square (kg/m^2) (BMI = weight/height^2), and a body weight of 50 to 100 kilogram (kg), inclusive
• Healthy on the basis of medical history, a physical examination, vital signs, and 12 lead electrocardiogram (ECG) performed at screening
• Healthy on the basis of clinical laboratory tests performed at screening and Day -1
• A woman must have a negative highly sensitive serum pregnancy test at screening and a negative urine pregnancy test on Day -1

Read More

Exclusion Criteria

• Has history of any clinically significant medical illness or medical disorders the investigator considers should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease
• Has a disease or disease treatment associated with immune suppression or lymphopenia, these include but are not limited to bone marrow or organ transplantation, lymphoproliferative disorders, T- or B-cell deficiency syndromes, splenectomy, functional asplenism, and chronic granulomatous disease
• Has a personal history of or conditions associated with thromboembolic events or bleeding disorders, including (but not limited to) myocardial infarction (MI), cerebral vascular accident (CVA)/stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), hemophilia, or menometrorrhagia
• Has history of allergy or adverse reactions to shellfish, aluminum, aluminum hydroxide keyhole limpet hemocyanin (KLH), tetanus or tetanus toxoid or its excipients
• Has a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or to any components of the formulation of JNJ-64232025 and its excipients used in this study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Single Ascending Dose (SAD) IV Cohort	Placebo	Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
Subcutaneous (SC) Cohort	JNJ-64232025 SC	Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
Subcutaneous (SC) Cohort	Placebo	Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
Single Ascending Dose (SAD) IV Cohort	JNJ-64232025 IV	Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.

Primary Outcome Measures

Name	Time	Method
Number of Participants with Treatment-Emergent Adverse Events (TEAE) by Severity	Up to Day 113	An adverse event (AE) is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship. The severity of the TEAEs will be assessed as mild, moderate, or severe.
Number of Participants with Serious Adverse Events (SAE)	Up to Day 113	An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Number of Participants with Clinically Significant Changes in Vital Signs	Up to Day 113	Number of participants with clinically significant changes in the vital signs including temperature, pulse/heart rate, respiratory rate, and blood pressure will be reported.
Number of Participants with ECG Abnormalities	Up to Day 113	Number of participants with electrocardiogram (ECG) abnormalities will be reported.
Number of Participants with Clinical Laboratory Abnormalities	Up to Day 113	Number of participants with clinical laboratory abnormalities, including cytomegalovirus (CMV) and Epstein-Barr virus (EBV) viral loads, will be reported.

Secondary Outcome Measures

Name	Time	Method
Maximum Observed Plasma Concentration (Cmax) of JNJ-64232025	Up to Day 113	The Cmax is the maximum observed plasma concentration of JNJ-64232025.
Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-64232025	Up to Day 113	The Tmax is defined as actual sampling time to reach maximum observed plasma concentration of JNJ-64232025.
Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity with Extrapolation of the Terminal Phase (AUC[0-infinity])	Up to Day 113	The AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(0-last) and C(0-last)/lambda(z); wherein AUC(0-last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(0-last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
Area Under the Plasma Concentration-Time Curve from Time Zero to the Time Corresponding to the Last Quantifiable Concentration (AUC[0-last])	Up to Day 113	The AUC(0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.
Terminal Half-Life (t1/2)	Up to Day 113	The t1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
Relative SC Bioavailability (F%)	Up to Day 113	Relative SC bioavailability will be calculated using the following equation: F (%\[percent\]) = AUC(0-infinity),SC/ mean AUC(0-infinity),IV \*100%.
Number of Participants with Anti-JNJ 64232025 Antibodies	Up to Day 113	Number of participants with anti-JNJ-64232025 antibodies will be assessed.
Total Systemic Clearance (C/L)	Up to Day 113	Systemic clearance is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).
Apparent Total Systemic Clearance After Extravascular Administration (CL/F)	Up to Day 113	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F is the apparent total systemic clearance after extravascular administration.
Volume of Distribution Based on Terminal Phase (Vz)	Up to Day 113	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
Apparent Volume of Distribution Based on Terminal Phase After Extravascular Administration (Vz/F)	Up to Day 113	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (Vz/F) is influenced by the fraction absorbed.
Number of Participants with Anti-KLH and Anti-Tetanus Antibodies	Up to Day 113	Number of participants with antibodies to anti-Keyhole Limpet Hemocyanin (KLH) and anti-tetanus will be assessed.

Trial Locations

Locations (1)

SGS Life Science Services; 🇧🇪 Antwerpen, Belgium